Trial Profile
A Retrospective, Single-Center Study Evaluating Survival of Crizotinib Continuation Plus Brain Radiotherapy in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients with Brain Metastases during Crizotinib Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jun 2018
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.